All posts by medical

Fantastic Muscle Proteins and Where To Find Them – Technology Networks

Setting out to identify all proteins that make up the sarcomere, the basic contractile unit of muscle cells, resulted in an unexpected revelation, providing experimental evidence that helps explain a fundamental mystery about how muscles work.Researchers at the Max Delbrck Center for Molecular Medicine in the Helmholtz Association (MDC) developed a mouse model that enables them to look inside a working muscle and identify the proteins that allow the sarcomere to contract, relax, communicate its energy needs, and adapt to exercise. Specifically, they were able to map proteins in defined subregions of the sarcomere, starting from the Z-disc, the boundary between neighboring sarcomeres. This in and of itself was a significant step forward in the study of striated muscle.

In the process, they made an unexpected discovery: myosin, one of the three main proteins that make up striated muscle fibers, appears to enter the Z-disc. Models of how myosin, actin and the elastic scaffold protein titin work together have largely ignored the possibility that myosin filaments penetrate the Z-disc structure. Only recently have German scientists theorized that they do, but no experimental evidence has validated the model, until now.

This is going to be unexpected even for myosin researchers, says Professor Michael Gotthardt, who heads MDCs Neuromuscular and Cardiovascular Cell Biology Lab and led the research. It gets to the very basics of how muscles generate force.

Sarcomeres are tiny molecular machines, packed with proteins that tightly interact. Until now it has been impossible to separate proteins specific to the different subregions, especially in live, functioning muscle. Titin-BioID probes specific regions of the sarcomere structure in vivo, says Dr. Philipp Mertins, who heads MDCs Proteomics Lab. This has not been possible before.

The team is the first to use BioID in live animals under physiological conditions and identified 450 proteins associated with the sarcomere, of which about half were already known. They found striking differences between heart and skeletal muscle, and adult versus neonatal mice, which relate to sarcomere structure, signaling and metabolism. These differences reflect the need of adult tissue to optimize performance and energy production versus growth and remodeling in neonatal tissue.

We wanted to know whos there, know who the players are, Gotthardt says. Most were expected, validating our approach.

This so-called sliding filament model of the sarcomere describes force production and helps explain how force and sarcomere length relate. However, current models have trouble predicting the behavior of fully contracted sarcomeres. Those models have assumed myosin does not enter the Z-disc on its walk along actin. There have been some hints that maybe it keeps going. But we didnt know if what we were seeing in stained tissue samples was an artefact or real life, Gotthardt says. With BioID we can sit at the Z-disc and watch myosin pass by.

Gotthardt agrees with the proposed theory that myosin entering the Z-disc can limit or dampen the contraction. This might help solve the ongoing issue scientists have had calculating how much force a muscle fiber can create in relation to its length and lead to a refined model of the sarcomere and possibly serve to protect muscle from excessive contraction.

Gotthardt and his team plan to next use BioID to study animals with different pathologies, to see what proteins are involved in muscle atrophy, for example. Maybe a protein that is not normally there goes into the sarcomere, and it is part of the pathology, Gotthardt says. We can find it with BioID.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more here:
Fantastic Muscle Proteins and Where To Find Them - Technology Networks

Bioactive Coating Devices Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026 – Cole of…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Bioactive Coating Devices market.

Trusted Business Insights presents an updated and Latest Study on Bioactive Coating Devices Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Bioactive Coating Devices market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Bioactive Coating Devices Market 2020 (Includes Business Impact of COVID-19)

Global Bioactive Coating Devices Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global bioactive coating devices market report has been segmented on the basis of product type, application, material, end user, and region

Request Covid 19 Impact

Global Bioactive Coating Devices Market: Overview

Blood clotting creates on obstruction for the implantable device to perform and can also result in devices failure which is a major concern among orthopedic and other doctors. Bioactive compounds allow direct bonding of living tissues and osteoconduction. Continuous research and development activities are being carried out in order for the development of new implantable devices that have a thin film of bioactive molecules or drugs. These devices aid in preventing device failure and inflammation and also enhances the integration of the device with the tissues

Global Bioactive Coating Devices Market: Dynamics

Increasing adoption of various implantable medical devices, such as stents, heart valves, etc. in order to improve patients lives, coupled with rising adoption of bioactive coating in order to control the failure of implantable devices is a major factor expected to drive growth of the global bioactive coating devices market

In addition, increasing prevalence of chronic diseases such as systemic joint, cardiovascular diseases, etc. across the globe, rising government spending on development of healthcare infrastructure, and shifting focus on cell biology and reduction of antimicrobial contamination in order to restrict usage of antibiotics are among other factors expected to further boost the market growth.

However, high cost of R&D activities and lack of infrastructural facilities are some major factors expected to hamper growth of the global bioactive coating market. In addition, stringent government regulations related to product approval is another factor expected to further challenge the growth of the global market.

Increasing investment by major players for technological advancements and R&D activities are expected to create new opportunities in terms of revenue for players operating in the global market over the forecast period. In addition, growing public-private partnership for R&D activities and innovative product offerings is expected to further support growth of the global market to a certain extent.

Global Bioactive Coating Devices Market: Segment

Among the product type segments, the drug-eluting coating segment is expected to dominate in the target market over the forecast period

Among the application segments, the hospital segment is expected to witness moderate growth in the target market over the forecast period

Global Bioactive Coating Devices Market: Region

The market in North American is expected to dominate the global bioactive coating market and is expected to continue its dominance over the forecast period. This dominance can be attributed to well-developed healthcare infrastructure for R&D activities, increasing adoption of implants, favorable reimbursement policies, and the presence of major players operating in the countries in this region. In addition, growing merger and acquisition activities between regional and international players is expected to further support the market growth in this region.

The market in Asia Pacific is expected to witness faster growth, owing to changing regulatory scenario, and the increasing presence of major manufacturers in emerging economies in this region. In addition, increasing government expenditure on the development of healthcare infrastructure is resulting in technological advancements in medical devices by regional players.

Global Bioactive Coating Devices Market Segmentation:

Segmentation by product type

Anti-microbial CoatingsHydrophilic CoatingsDrug Eluting CoatingOthers (including Anti-thrombogenic Coatings)

Segmentation by application

StentsCardiac assist devicesElectrosurgical toolsCochlear and ocular implantsMandrels and moldsCathetersOthers (Elastomeric seals, Needles and epidural probes, Medical electronics)

Segmentation by material

Biological MaterialsCarbon-Based MaterialsMetals and AlloysPolymers and Synthetic

Segmentation by end user

HospitalDiagnostics CentersAmbulatory Surgical CentersClinics

Quick Read Table of Contents of this Report @ Global Bioactive Coating Devices Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See more here:
Bioactive Coating Devices Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026 - Cole of...

Covid-19 Lockdown Impact On Global Live Cell Imaging Market Growth and Demand, Projected MarketResearchStore – Cole of Duty

Live Cell Imaging Industry Overview Competitive Analysis, Regional and Global Analysis, Segment Analysis, Market Forecasts 2026

The globalLive Cell Imaging marketshave undergone huge change in the last few months. These changes were due to the outbreak of the pandemic which was first detected in the Wuhan city of China. COVID-19 which has occurred due to the coronavirus has taken many lives of people around the world. As the disease is spreading at a rapid rate many of the countries have ordered lockdown for maintaining social distancing. Due to the lockdown, many of the industries have halted their manufacturing units. There have been restrictions for cross border trading within the countries and also within the states. Owing to these conditions, trading conditions in various regions have been affected badly. The overall countries in the world are facing economic crisis thus affecting some of the major markets in the world.

Request Free Sample Copy of Live Cell Imaging Market Research Report@http://www.marketresearchstore.com/report/global-live-cell-imaging-market-report-2018-industry-366843#RequestSample

The research analysts from theMarket Research Storehave conducted a detailed study about the global Live Cell Imaging market. Owing to the above mentioned conditions, the global Live Cell Imaging market has undergone several changes on the global platform. All these updates are mentioned in the Live Cell Imaging market report study. The research analysts have conducted a thorough primary and secondary research for updating the market statistics as per the current market scenario. The detailed Live Cell Imaging market report is of over 150 pages including more than 30 tables and around 20 figures. The report includes pictorial representations of the market data in order to understand the Live Cell Imaging market in a simple and easy way.

The data that is included about the Live Cell Imaging market incorporates historical data from 2016 to 2019 and forecasts data from 2020 to 2026. The major players that are functioning in the Live Cell Imaging market areBecton, Dickinson and Company (U.S.), PerkinElmer, Inc. (U.S.), Olympus Corporation (Japan), Nikon Corporation (Japan), GE Healthcare (U.K.), Thermo Fisher Scientific, Inc.(U.S.), Sigma Aldrich Corporation (U.S.), Leica Microsystems (Germany), Carl Zeiss. Details about all the market players, distributors, suppliers, and retailers are profiled in the Live Cell Imaging market report.

Read Detailed Index of full Research Study at::http://www.marketresearchstore.com/report/global-live-cell-imaging-market-report-2018-industry-366843

The Live Cell Imaging market is segmented into{Equipment, Consumables}; {Cell Biology, Stem Cells, Developmental Biology, Drug Discovery}. Each of the market segments is described in detail within the report. Data about the segments are represented in both qualitative and quantitative format, thus enabling to understand the market in detail.

Major Advantages for Live Cell Imaging Market:

Well-organized description of the international Live Cell Imaging market along with the ongoing inclinations and future considerations to reveal the upcoming investment areas. The all-inclusive market feasibility is examined to figure out the profit-making trends to obtain the most powerful foothold in the Live Cell Imaging industry. The Live Cell Imaging market report covers data which reveal major drivers, constraints, and openings with extensive impact analysis. The current market is quantitatively reviewed from 2019 to 2028 to pinpoint the monetary competency of the global Live Cell Imaging market. Last but not least, PORTERS Five Forces Analysis shows the effectiveness of the customers and providers from a global perspective.

If Any Inquiry of Live Cell Imaging Report:http://www.marketresearchstore.com/report/global-live-cell-imaging-market-report-2018-industry-366843#InquiryForBuying

View post:
Covid-19 Lockdown Impact On Global Live Cell Imaging Market Growth and Demand, Projected MarketResearchStore - Cole of Duty

Massive proteomics investigation of COVID-19 infection – News-Medical.Net

Researchers from Germany and Switzerland revealed functional effects of individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins on cellular level after infection. They placed the findings into the context of host signaling pathways in order to identify vulnerable parts of the virus amenable to treatment. The study is currently available on the bioRxiv* preprint server.

The sudden global emergence of SARS-CoV-2, the causative agent of an ongoing coronavirus disease (COVID-19) pandemic, prompted the need for an in-depth apprehension of molecular functions of viral proteins and their respective interactions with the host proteome.

Several omics studies have broadened our knowledge of COVID-19 pathophysiology, including some that were focused on proteomic aspects. For example, a comprehensive SARS-CoV-2 human protein-protein interaction map (derived with affinity-purification mass spectrometry) was recently published in the leading scientific journal Nature.

But albeit multi-omics studies (together with structural biology methods) are anticipated to have a fundamental role in the efficient clinical management of this pandemic, systems-level molecular studies of SARS-CoV-2 are hampered by the tremendously contagious nature of the pathogen.

However, there are scientists ready to tackle such challenging research questions. In order to understand the exact way how SARS-CoV-2 and related coronaviruses manipulate the host, a research group from Germany and Switzerland recently characterized proteome, interactome, and signaling processes in a systems-wide manner.

These researchers investigated closely related SARS-CoV-2 and SARS-CoV viruses (the latter being the causative agent of the original SARS outbreak), as well as the influence of SARS-CoV-2 on the proteome, transcriptome, ubiquitinome, and phosphoproteome of a lung-derived human cell line.

More specifically, to acquire information on the concerted activity of viral proteins during the infection, they have infected A549 cells expressing ACE2 receptor with SARS-CoV-2 and characterized the impact of viral infection on RNA transcription, protein abundance, ubiquitination (i.e., bonding of a ubiquitin-protein to a substrate protein) and phosphorylation in a time-resolved manner

"For each viral protein, we mapped the collected data onto the global network of cellular interactions and applied a network diffusion approach," further explain study authors. "Such analysis identifies short links of known protein-protein interactions, signaling and regulation events that connect the interactors of the viral protein with the proteins affected by its expression," they add.

Such an analysis of proteome changes (induced by each viral protein) and consideration of subsequent protein interactions provided direct insights into their functions. Finally, the researchers tested a panel of 48 drugs modifying the pathways perturbed by the virus for their effects on SARS-CoV-2 replication.

The virus-host interaction network that stemmed from this comprehensive research endeavor revealed a myriad of cellular activities intercepted by both SARS-CoV-2 and SARS-CoV. The systematic proteome and interactome profiling of individual viral proteins opened the door for a deeper understanding of their molecular mechanisms.

More specifically, when SARS-CoV-2 is concerned, this study found that it can interact with specific protein complexes, contributing in turn to a range of biological processes. Moreover, the virus can also target stress response components and DNA damage response mediators.

"Upon virus infection, we observed upregulation of TGF- and EGFR pathways, which modulate cell survival, motility, and innate immune responses," said study authors. "Besides promoting virus replication, activation of these pathways has been implicated in fibrosis, one of the hallmarks of COVID-19", they further emphasize.

According to the drug testing results, B-RAF, JAK1/2, and MAPK inhibitors led to a significant increase of viral growth in the laboratory infection setting; conversely, tyrosine kinase inhibitors, the mTOR inhibitor, or inducers of DNA damage led to the suppression of SARS-CoV-2.

In a nutshell, projecting the obtained data onto the global network of cellular interactions unveiled relationships between the perturbations that arise upon SARS-CoV-2 infection at different layers, but also identified unique and characteristic molecular mechanisms of SARS coronaviruses.

Taken together, the illustrated viral-host protein-protein interactions and pathway regulations that were observed at multiple levels recognize potential areas of SARS-CoV-2 that could be targeted by well-characterized selective antiviral drugs.

"The results highlight the functionality of individual proteins, as well as vulnerability hotspots of SARS-CoV-2, which we targeted with clinically approved drugs", explain study authors. "We exemplify this by identification of kinase inhibitors, as well as matrix metallopeptidase inhibitors with significant antiviral effects against SARS-CoV-2", they add.

Furthermore, the drug screen that was pursued in this study demonstrated the value of this type of combined dataset, and further exploration of the interplay between different -omics levels may advance the knowledge of coronavirus biology and pathogenicity.

In conclusion, these results can serve as a base for the intelligent design of combination therapies that target the virus from multiple and synergistic angles, potentiating, in turn, the effect of individual treatments, and minimizing at the same time the side-effects on healthy tissues.

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

See the article here:
Massive proteomics investigation of COVID-19 infection - News-Medical.Net

Medical Imaging Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario – Cole of Duty

The global market for medical imaging should grow from $34.1 billion in 2018 to reach $43.6 billion by 2023 at a compound annual growth rate (CAGR) of 5.1% for the period of 2018-2023.

Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/11622

Report Scope:

The scope of this report is broad and covers various types of products available in the medical imaging instruments market and potential application sectors across various industries. The medical imaging instruments market is broken down into product types such as X-ray systems, ultrasound devices, MRI, CT and nuclear imaging. Revenue forecasts from 2018 to 2023 are given for each product type, technologies, application and end users with estimated valued derived from the revenue of manufacturers total revenues.

The report also includes a discussion of the major players across each regional medical imaging instrument market. It explains the major drivers and regional dynamics of the global medical imaging instruments market and current trends within the industry. An analysis of the regulatory scenario that governs the medical imaging industry is also included in the scope of this report.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the global medical imaging instruments market.

Report Includes:

101 data tables and 108 additional tables Country specific data and analysis for United States, Canada, Mexico, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Australia, Middle East, Africa and Latin America Detailed description of innovative imaging modalities such as mammography and 3D ultrasonic holography Identification of research areas for biomedical imaging and applications of biophotonics and biomedical imaging in research Comparative study of focused ultrasound with an ideal surgical tool and study challenges that need to be addressed in global medical imaging instruments market to achieve fiscal succes Identification of various strategies adopted by market players to enhance their market position, including expansion, product launch, acquisition and merger, innovation, partnership and joint venture Company profiles of major players in the market, including Agfa Healthcare, Boston Scientific, Bruker Corp., Canon, Inc. and GE Healthcare

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/11622

Summary

Due to the prevalence of chronic diseases coupled with the increasing geriatric population and number of road accidents, stronger demand for better imaging has emerged. Chronic diseases such as cancer, strokes, neurodegenerative diseases, COPD (chronic obstructive pulmonary disease), cardiovascular diseases and others require imaging of body parts for proper diagnosis of the disease.

According to the World Health Organization (WHO), the major diseases that lead most NCD (noncommunicable diseases) deaths are cardiovascular diseases, cancers, respiratory diseases and diabetes, accounting for more than 80% of all premature NCD deaths. NCDs claim 40 million deaths each year and account for approximately 70% of global deaths. Such high instances of chronic diseases require improved and advanced imaging technologies such as MRI, ultrasound and others. Also, the number of road accidents calls for the imaging technologies in cases of major and minor fractures.

According to the World Health Organization (Switzerland), nearly 1.24 million people throughout the world die each year due to road traffic crashes that equates to ~3,400 deaths per day. Imaging instruments find huge application in cases of fractures. Factors such as prevalence of chronic diseases and an increasing geriatric population, coupled with increasing demand of 3D medical imaging equipment, are also providing traction to the global medical imaging instruments market.

Companies are focusing on the continuous development of products that support novel imaging technologies such as colored and 3D imaging due to their rising demand. Surging investments on technological advancements for increasing resolution and pixel capabilities, wider disease detection capabilities and more advanced software can be observed in the market. For instance, in 2017, Royal Philips (Netherlands) announced a new MRI system, MR Prodiva 1.5T, with enhanced clinical performance, workflow, and capability of 2D and 3D scans. Similarly, launched in November 2017 by NPL (National Physical Laboratory), 3D OrbiSIMSis a molecular imaging instrument used to explore potentials under cell biology and drug discovery.

The imaging technologies are used across various end users including hospitals, diagnostic centers and research centers. In hospitals, the imaging instruments are used for imaging body parts in cases of chronic diseases or accidents. In diagnostic centers, the imaging instruments are widely adopted for diagnosing a particular body part or the whole body. The imaging instruments are used for molecular imaging in the research centers for drug discovery purposes.

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/11622

The global medical imaging market is projected to rise at a CAGR of REDACTED during the forecast period of 2018-2023. By 2023, total revenue is expected to reach nearly REDACTED, with an increase of REDACTED from REDACTED in 2017.

The report provides an analysis based on each product type segment, which includes X-ray systems, magnetic resource imaging equipment/instruments, CT scanners, ultrasound systems and nuclear imaging equipment/instruments.

Read more here:
Medical Imaging Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario - Cole of Duty

Neuroscience Antibodies and Assays Market Share, Growth, Statistics, by Application, Production, Revenue & Forecast to 2025 – Jewish Life News

Market Study Report Adds New, 2020-2025 Global Neuroscience Antibodies and Assays Industry Market Report to its research database presenting an informative study covering the market with detailed analysis. The Global Neuroscience Antibodies and Assays Industry market research report is a professional and in-depth study on the current state of global Industry.

This Neuroscience Antibodies and Assays Industry market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timeframe.

Request a sample Report of Neuroscience Antibodies and Assays Industry Market at:https://www.marketstudyreport.com/request-a-sample/2729193

The report is also inclusive of some of the major development trends that characterize the Neuroscience Antibodies and Assays Industry market. A comprehensive document in itself, the Neuroscience Antibodies and Assays Industry market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Neuroscience Antibodies and Assays Industry market study is comprised of parameters such as the impact of the current market scenario on investors.

The pros and cons of the enterprise products, a detailed scientific analysis pertaining to the raw material as well as industry downstream buyers, in conjunction with a gist of the enterprise competition trends are some of the other aspects included in this report.

How has the competitive landscape of this industry been categorized?

Regional landscape: How will the details provided in the report help prominent stakeholders?

Ask for Discount on Neuroscience Antibodies and Assays Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2729193

Other pivotal aspects encompassed in the Neuroscience Antibodies and Assays Industry market study:

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-neuroscience-antibodies-and-assays-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Remote Patient Monitoring Systems Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-remote-patient-monitoring-systems-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Aerial Working Platform Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-aerial-working-platform-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Continued here:
Neuroscience Antibodies and Assays Market Share, Growth, Statistics, by Application, Production, Revenue & Forecast to 2025 - Jewish Life News

COVID-19 Survey Shows One-Third of Researchers Could Leave Neuroscience – Technology Networks

A UK-wide survey has exposed the damaging effects of the COVID-19 pandemic on neuroscience research. A third of respondents to the survey, organized by the British Neuroscience Association (BNA), said that they were considering leaving the field. Nearly nine in ten respondents felt that the pandemic had had a negative impact on their research. The survey, recorded between May and June, highlights the wide-ranging impacts of the pandemic across academia, the full effects of which are still to be felt.The survey findings were published yesterday (18th June) by the BNA. The findings reveal huge anxiety among researchers around the future of their work in a post-pandemic world.

The survey found that researchers had felt immediate impacts of COVID-19 on their work:

Over 400 neuroscience researchers from around the UK contributed to the survey, with the majority of respondents in early career researcher positions. The survey showed an uncertain outlook for researchers whose external funding timelines have been thrown into jeopardy. Over a quarter of researchers had requested further funding to maintain their research. Worryingly, just under half of these respondents reported that their requests had gone unanswered.The survey included quotes from respondents that bring into sharp focus the human cost of a field put into stasis. My fellowship is due to finish next year. We have received a three-month salary extension and a six-month extension to the end date. However, this year was the key year to be collecting the data after several years of training the animals and developing the new techniques to use in my lab. I am worried that there won't be enough time to re-train the animals and complete all the experiments in time. We have had to maintain the implants on the animals, which has been difficult as we continue to go into work and clean them but can't train them or collect any data from them, said a senior academic behavioural scientist who contributed to the survey.

Speaking to Technology NetworksAnne Cooke, CEO of the BNA, said the most concerning reports from the survey were about the number of researcher looking to a future outside of science. The most worrying and surprising finding was about the number of people who are considering or really think they will have to leave frontline neuroscience research as a direct result of coronavirus. I think we anticipated responses that the impact had been negative, but I think the finding that people really thought they wouldn't be able to carry on was, for me, the most shocking result.

The early stages of research have a notoriously high attrition rate, but Cooke said that some of the respondents insights suggest that COVID-19 is exerting an additional pressure to leave the sector. One of our next steps will be digging into these key findings more, said Cooke. When you look at the career pyramid in science, you get a lot of early-career researchers who leave science naturally. But when we looked at the comments behind the survey, we realized that this is a direct result of coronavirus, this isnt just the natural career progression attrition that you get at that stage.

Cooke continued, People commenting on the fact that they've had to look after children at home has had a really detrimental effect. They are no longer going to be able to compete their research project. They therefore don't think they'll get the next fellowship or the next set of funding.

Whilst around half of respondents hoped that their work will resume pre-lockdown levels by the end of 2020, four out of five believed that this progress will be hindered by insufficient funding. Additional concerns for respondents included:

The BNA have written a letter to the science minister, Amanda Solloway MP, asking for clarity on how existing projects will be brought back on track.Joseph Clift, the BNAs head of policy, said any response should support researchers as they return to the workplace and also secure supplies of lab equipment that have been disrupted by the pandemic. What researchers need now is little bit more detail on how those funds can help support efforts to salvage research, said Clift.

Follow this link:
COVID-19 Survey Shows One-Third of Researchers Could Leave Neuroscience - Technology Networks

What Innovations, Technologies Are Emerging in the Pipeline of Parkinson Disease Treatment? – AJMC.com Managed Markets Network

Central nervous system gene therapies and advanced technologies to provide these treatments were noted as emerging opportunities in treatment for neurological conditions such as Parkinson disease, according to review findings. Researchers also highlighted the lack of experience and technology in medical centers nationwide to provide these services.

Currently, vector-based intracerebral gene therapies are being used to treat specific neurodegenerative conditions. While these therapies have been included in clinical trials for PD and other similar conditions, there has yet to be a breakthrough treatment.

However, researchers note that new molecular agents, device innovations, and improved neurosurgical techniques have unlocked the potential of therapies delivered directly via infusion into the CNS. With this opportunity emerging, they sought to review how these CNS gene therapy treatments performed in neurological diseases, as well as if skill sets and health delivery strategies within the clinical neuroscience practices are aligned with future demand for these therapies.

Focusing on patients with idiopathic PD, researchers referenced image-guided convection enhanced delivery (CED) as optimizing the parenchymal distribution of gene therapies applied within the CNS. Citing this as the potential therapeutic breakthrough, researchers then highlighted how image-guided CED and gene therapy are not part of training programs for most neurosurgeons and neurologists. This could prove to lessen the impact among patients as treatment will be limited by factors such as geographic location and specialization.

If CNS gene therapies prove to be efficacious for PD and/or other conditions, the demand for such treatments will overwhelm the available number of experienced clinical neuroscience teams and treatment centres, warned the study authors.

To address this potential demand, researchers said that a worldwide education effort to provide this training to clinical neuroscience practitioners would be warranted. Moreover, they say to begin this transition, at least a limited number of Centers of Excellence will need to establish relevant educational training requirements and best practice for these therapies.

The crucial availability of advanced technologies, such as robotics and artificial intelligence, were then cited by researchers as they will expand the treatment team's capabilities while assisting in the safe and timely care of those afflicted.

Reference

Fiandaca MS, Lonser RR, Elder JB, et al. Advancing gene therapies, methods, and technologies for Parkinson disease and other neurological disorders. Neurol Neurochir Pol. Published online June 18, 2020. doi:10.5603/PJNNS.a2020.0046

View original post here:
What Innovations, Technologies Are Emerging in the Pipeline of Parkinson Disease Treatment? - AJMC.com Managed Markets Network

AMSA and Sunovion Team Up For Second Year of Neuroscience Peer Teaching Program While Transitioning to Remote Learning Experience – Business Wire

MARLBOROUGH, Mass.--(BUSINESS WIRE)--The Advanced Math & Science Academy Charter School (AMSA) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced completion of the second year of a program to help students understand Science, Technology, Engineering and Math (STEM) life science career paths within a pharmaceutical company and foster a deeper knowledge of neuroscience. Six AMSA upper school level students, five seniors and one junior, were selected as a team to participate in this collaborative project with Sunovion for their schools Capstone Project. Due to the Commonwealth of Massachusetts response to COVID-19 and schools moving to remote learning for the remainder of the 2020 school year, Sunovion and AMSA worked together to adjust and transition the program to a virtual experience.

The high school student team developed a lesson plan about the central and peripheral nervous systems that they successfully taught seventh grade students at AMSA via a video classroom, with the goal to enhance and complement their existing biology class curriculum. This material was developed in consultation with a cross-functional team from Sunovion with a range of expertise.

Our goal at AMSA is to create an atmosphere of celebration of knowledge where children of diverse backgrounds and abilities excel, especially in math, science and technology, and we empower them to succeed in the workplace in our modern high-tech world. The partnership between AMSA and Sunovion was what AMSA founders envisioned in our charter with the State, when they located the school in Marlborough for close proximity to a growing innovation ecosystem. AMSA is proud of this program, which has leveraged access to Sunovions in-depth expertise to enhance our science education. We thank the Sunovion team for their positive impact and inspiring our students, said Ellen Linzey, Executive Director, AMSA.

This important program with AMSA reinforces our commitment to advancing the next generation of innovators and leaders and we appreciate the continued collaboration with administrators and faculty. We were impressed by the students and their ability to absorb and convey complex neurobiology information to their peers in an accessible way. They adapted to a remote peer teaching environment this year with great effectiveness and success, said Ken Koblan, PhD, Chief Scientific Officer, who serves as Sunovions executive sponsor of the program with AMSA.

The student teachers were honored during a virtual ceremony on May 13, 2020 as they look forward to the next chapters in their academic careers and consider pursuing further learning in healthcare, the life sciences, or neurobiology. Seniors were provided with certificates and scholarships upon completion of their Capstone Project. The program was initiated in 2019 through the collaboration of Mark Vital, Community Outreach Manager, AMSA and Wendy Scoppa, Senior Manager, Community Relations, Sunovion. A video of the ceremony and project can be viewed here.

About Advanced Math & Science Academy (AMSA)

Ranked as the #4 public high school in Massachusetts by U.S. News & World Report, The Advanced Math & Science Academy Charter School (AMSA) was chartered by the Massachusetts Department of Education in February 2004 and opened in September 2005. AMSAs teaching model is centered on rigorous college-oriented education for all students. AMSAs teaching philosophy involves starting challenging abstract learning, typically expected for high school students, early in the middle school grades. AMSA creates an atmosphere of celebration of knowledge where children of all backgrounds and abilities excel in all subjects, especially in math, science and technology, empowering them to succeed in the workplace in our modern, high-tech world. AMSA's core values are collective and individual values: Model Integrity, Pursue Your Excellence and Foster Community. Learn more about AMSA at http://www.amsacs.org and join AMSA on social media at http://www.amsacs.org/social.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovions vision is to lead the way to a healthier world. The companys spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions. Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the companys web sites: http://www.sunovion.com, http://www.sunovion.eu and http://www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

See the rest here:
AMSA and Sunovion Team Up For Second Year of Neuroscience Peer Teaching Program While Transitioning to Remote Learning Experience - Business Wire

Engrail Therapeutics Raises $32 Million in Series A Financing – Business Wire

SAN DIEGO--(BUSINESS WIRE)--Engrail Therapeutics (Engrail) (the Company) today announced the close of a $32 million Series A financing round. Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led the round. The Company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator.

Neuroscience is making massive strides. As the brains complexities and molecular mechanisms have become clearer, we are better able to identify disease targets, which has also a supported a resurgence in funding neuroscience drug development, said Vikram Sudarsan, Ph.D., CEO and president, Engrail Therapeutics. These factors have contributed to recent clinical and commercial success across the industry. However, significant unmet needs persist, placing immense disease burden on patients. Our goal is to build a leading neuroscience company fueled by a robust pipeline. We are focused on the acquisition, development and commercialization of patient-centric neuroscience therapeutics. ENX-101 represents the first milestone in this effort.

Dr. Sudarsan continued, We are pleased to close this financing round with a world-class investor who believes in the bold vision of our new company. With these resources and a long-term commitment from NFLS to invest $1.5 billion in the life sciences sector, we will leverage our unique, flexible transaction model to build a world-class neuroscience company.

Engrail adopts a 'science-first' approach that begins with a thorough biological understanding of disease and rational therapeutic targeting, enabling the Company to identify compounds with greater opportunity to address patient unmet needs. This, combined with a comprehensive view of clinical development strategy, regulatory considerations, intellectual property and optimal commercial positioning, allows Engrail to acquire high-quality assets with a lower-risk path to market. The Company expects to acquire assets with validated mechanisms, ultimately catalyzing a diverse portfolio of therapies to treat diseases of the nervous system. Engrails flexible transaction model includes licensing, co-development and company acquisitions.

Engrails dynamic model for advancing drugs aimed at treating life-limiting diseases of the nervous system is exactly the innovation this complex field requires, said Peter Bisgaard, managing director of NFLS and chairman of Engrails board of directors. We look forward to supporting Engrails team of passionate entrepreneurs as it acquires assets and moves these compelling therapies through the clinic.

About Engrail Therapeutics

Founded in 2019, Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences. For more information, visit http://www.engrail.com.

About Nan Fung Life Sciences

Nan Fung Life Sciences is a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group. Our team possesses diverse experience with long track records in company formation, venture capital, growth/buyout investments, and drug discovery and development. Through direct investments via Pivotal bioVenture Partners US and Pivotal bioVenture Partners China as well as fund investments, we cover the full spectrum of the life sciences industry including therapeutics, medical devices and diagnostics and across all development stages. To learn more, visit http://www.nanfunglifesciences.com.

Read this article:
Engrail Therapeutics Raises $32 Million in Series A Financing - Business Wire